SCHEMBL5486801

SCHEMBL5486801

O=C(Nc1cccc(Cl)c1)Nc1cccc(-c2cn3ccnc3c(NCc3ccncc3)n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 20/20 1.00
ABL1 P00519 1/20 0.78
EGFR P00533 1/20 0.78
PRKCB P05771 1/20 0.78
INSR P06213 1/20 0.78
LCK P06239 1/20 0.78
FYN P06241 1/20 0.78
LYN P07948 1/20 0.78
PDGFRB P09619 1/20 0.78
SRC P12931 1/20 0.78
PRKCA P17252 1/20 0.78
FLT1 P17948 1/20 0.78
FGFR4 P22455 1/20 0.78
EPHA2 P29317 1/20 0.78
AKT1 P31749 1/20 0.78
FLT4 P35916 1/20 0.78
KDR P35968 1/20 0.78
FLT3 P36888 1/20 0.78
ZAP70 P43403 1/20 0.78
SYK P43405 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478632 0.94 EPHB4 (1.00) EPHB4
SCHEMBL5478639 0.91 EPHB4 (0.86) EPHB4ABL1EGFRPRKCBINSR
SCHEMBL5485541 0.90 EPHB4 (1.00) EPHB4
SCHEMBL5486306 0.90 EPHB4 (1.00) EPHB4ABL1EGFRPRKCBINSR
SCHEMBL6204144 0.90 EPHB4 (0.92) EPHB4
SCHEMBL6221241 0.89 EPHB4 (0.84) EPHB4
SCHEMBL5482521 0.89 EPHB4 (0.85) EPHB4ABL1EGFRPRKCBINSR
SCHEMBL5488557 0.89 EPHB4 (1.00) EPHB4KDRTEK
SCHEMBL5480341 0.88 EPHB4 (0.85) EPHB4KDRTEK
SCHEMBL5480112 0.87 EPHB4 (1.00) EPHB4ABL1EGFRPRKCBINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259164-B2 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity CGI PHARMACEUTICALS, INC. (US) 2007-08-21 US claimed
WO-2005019220-A9 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS INC (US) 2005-06-02 WO claimed
US-20050085484-A1 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity GILEAD CONNECTICUT, INC. 2005-04-21 US claimed
WO-2005019220-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS INC. (US) 2005-03-03 WO claimed
US-7259164-B2 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity CGI PHARMACEUTICALS, INC. (US) 2007-08-21 US disclosed
US-7259164-B2 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity CGI PHARMACEUTICALS, INC. (US) 2007-08-21 US disclosed
WO-2005019220-A9 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS INC (US) 2005-06-02 WO disclosed
US-20050085484-A1 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity GILEAD CONNECTICUT, INC. 2005-04-21 US disclosed
WO-2005019220-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085484-A1 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity ERBB4, MAP4K4, EPHB4 EPHB4 3/4885ABL1 522/4885EGFR 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.